InspireMD
Open
$1.17
Prev. Close
$1.17
High
$1.18
Low
$1.17
Market Snapshot
$48.3M
-1.0
-0.77
$7.01M
127
InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The company is headquartered in Miami, Florida and currently employs 85 full-time employees. The company went IPO on 2013-04-12. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
emptyResult
InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The company is headquartered in Miami, Florida and currently employs 85 full-time employees. The company went IPO on 2013-04-12. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Recently from Cashu
InspireMD Revolutionizes Cardiovascular Care with CGuard for Enhanced Patient Outcomes
InspireMD: Pioneering Innovation in Cardiovascular Treatment InspireMD, a company committed to advancing cardiovascular care, actively works to address the critical need for improved patient outcomes…
InspireMD: Advancing Cardiovascular Treatments Through Innovative Medical Technologies
InspireMD’s Role in Advancing Medical Technologies: A Critical Development InspireMD focuses on developing and commercializing innovative medical devices aimed at treating cardiovascular diseases, pos…
InspireMD: Innovating Cardiovascular Care with MGuard Stent Technology and Patient-Centered Solutions
InspireMD's Focus on Innovation in Cardiovascular Care InspireMD, a company specializing in innovative cardiovascular solutions, emphasizes its commitment to advancing medical technology to improve pa…
InspireMD Stock Update: Key Developments and Market Insights
Please provide the content you would like me to summarize, and I'll be happy to help!